This Is MS Multiple Sclerosis Community: Knowledge & Support

Chromos reports preclinical data in support of CHR-1103 as an acute therapy for relapse associated with multiple sclerosis
Brain Pathology paper has implications for treatment of MS.

Chromos Molecular Systems Inc. announced today the publication of a paper entitled "Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade" in the peer-reviewed scientific journal, Brain Pathology. This paper, authored in collaboration with Dr. Robert Fujinami of the University of Utah School of Medicine, demonstrates that a monoclonal antibody directed against VLA-2, the target for Chromos' lead product candidate CHR-1103, can suppress the clinical and pathological signs of disease in a relevant animal model of multiple sclerosis (MS). In addition, the publication validates VLA-2 as a potential target for early therapeutic intervention in the treatment of MS. This data represents a significant milestone in the development of CHR-1103 as an acute treatment for relapses associated with MS.

"We are very pleased with the release of this data as it represents the culmination of a tremendous body of work in support of the development of CHR-1103 as an acute treatment for MS relapse," said Alistair Duncan, President and CEO. "Currently, there are no FDA approved therapies for MS patients suffering from a relapse. CHR-1103 represents a promising new approach for the treatment of MS relapse and disease compared to the existing portfolio of chronically administered treatments."

CHR-1103 is a humanised monoclonal antibody being developed as a broad-based anti-inflammatory agent, with an initial focus on the treatment of acute relapses associated with MS. Unlike therapeutics designed to delay or antagonise the initial stages of inflammation, CHR-1103 is designed to reduce and prevent the accumulation of inflammatory cells within inflamed tissues. This distinction, i.e., the targeting of ongoing inflammation with CHR-1103, may provide a significant advantage for the acute treatment of inflammatory conditions and/or diseases.

Chromos completed its first meeting with officials from the U.S. Food and Drug Administration (FDA) for CHR-1103 in Q3 2006. The two parties discussed Chromos' clinical approach, proposed preclinical safety evaluation program and manufacture of CHR-1103. Chromos is now moving forward with preclinical safety evaluation studies in preparation for an Investigational New Drug (IND) application in Q4 2007.

RTL 1000 and CHR-1103
Wow, you're turning into a whirling dervish.....whatever that is.
Thanks Scooby...or whoever I am responding to.
He of mushbrain,
Bob

Later edit* I looked up whirling dervish up on the internet and you're not one...sorry! I guess I had previously thought it meant like a tireless female or super energetic fairy or something.

Bob, I'm just glad you got my name right That day happened to be a good day for MS research news. Personally I like to think of myself as an investigative crusader for MS!! Not really since I barely understand half the stuff I post Most of the time I have to wait until others can explain it to me. Research progress is what keeps me going.

Hi Scoob,
I know where you're coming from, I've said many times that I'm in over my head. I have no choice but to avoid the really technical stuff. I can't understand ANY of that.
Bob